Harris BS, Bishop KC, Kuller JA, et al. - Researchers investigated the role of hormone therapy in menopausal patients with breast cancer and gynecologic malignancies. Searching MEDLINE (via PubMed), they identified 1,484 relevant citations; all citations were imported into EndNote X9, where the citations were screened. The findings emphasize assessing the risks of hormone therapy on an individual basis, with consideration of age, type of hormone therapy, dose, duration of use, regimen, route, and prior exposure. As per the analysis, systemic hormone therapy should be avoided in breast cancer survivors, however, consideration could be given to local low-dose estrogen therapy following discussion with the patient's oncologist. Among endometrial cancer survivors, hormone therapy is recognized as safe in low-risk cancers but it is not recommended in high-risk subtypes. For survivors of epithelial ovarian cancer and cervical cancer, consideration could be given to hormone therapy, however, this therapy should be avoided in women with estrogen-sensitive histologic subtypes.